Φορτώνει......

FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer

BACKGROUND: Cetuximab, a monoclonal antibody against EGFR used for the treatment of colorectal cancer (CRC), is ineffective in many patients. The aim of this study was to identify the signalling pathways activated by cetuximab in CRC cells and define new biomarker of response. METHODS: We used in vi...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:	Br J Cancer
Κύριοι συγγραφείς:	Marzi, L, Combes, E, Vié, N, Ayrolles-Torro, A, Tosi, D, Desigaud, D, Perez-Gracia, E, Larbouret, C, Montagut, C, Iglesias, M, Jarlier, M, Denis, V, Linares, L K, Lam, E W-F, Martineau, P, Del Rio, M, Gongora, C
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Nature Publishing Group 2016
Θέματα:	Translational Therapeutics
Διαθέσιμο Online:	https://ncbi.nlm.nih.gov/pmc/articles/PMC5104890/ https://ncbi.nlm.nih.gov/pubmed/27685445 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.313
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer

Παρόμοια τεκμήρια